Published October 4, 2024 | Version v.1

Designing and the anticancer activity of chitosan and chitosan oligosaccharide lactate nanobeads loaded with Biginelli hybrid

  • 1. University of Kragujevac, Department of Science, Institute for Information Technologies KragujevacThe institution will open in a new tab, Jovana Cvijića bb, Kragujevac, 34000, Serbia
  • 2. University of Novi Sad, Faculty of MedicineThe institution will open in a new tab, Hajduk Veljkova 3, Novi Sad, 21000, Serbia
  • 3. Institute of Oncology and Radiology of Serbia
  • 4. Pasterova 14, Belgrade, 11000, Serbia
  • 5. The Institute for the Study of Medicinal Herbs "Dr Josif Pančić", Tadeuša Košćuška 1, Belgrade, 11000, Serbia
  • 6. Departement of Pharmaceutical Technology and Cosmetology
  • 7. ROR icon University of Belgrade – Faculty of Pharmacy
  • 8. Departement of Pharmaceutical Chemistry

Description

Abstract

This study focuses on the designing and characterization, and anticancer evaluation of chitosan-based nanoparticles (NPs) loaded (enriched) with a Biginelli hybrid compound (BH). NPs based on chitosan (CH) or chitosan oligosaccharide lactate (CHOL), are carefully designed to encapsulate a tetrahydropyrimidine derivative (BH) with already proven anticancer properties. The formulations were evaluated for their physicochemical properties, including particle size distribution and morphology, using techniques such as infrared spectroscopy, scanning electron microscopy, and X-ray diffraction. The cytotoxicity profiles were assessed on different cancer cell lines, showing a higher selectivity towards HeLa and A549 cells related to BH. BH-CH showed better cytotoxic profile related to BH-CHOL NPs. A cell cycle analysis revealed an accumulation of cells in the G2/M phase after a treatment with these NPs, indicating the ability to induce mitotic arrest in cancer cells. In summary, the results underscore the promising application of CH-based natural nanocarriers for the targeted delivery of Biginelli hybrids, showcasing a significant potential for further in vivo testing. © 2024 The Royal Society of Chemistry.

Notes (English)

This research was funded by the Ministry of Science, Technological Development, and Innovation of the Republic of Serbia on the research programs: Grant no. 451-03-66/2024-03/200378 (University of Kragujevac, Institute for Information Technologies) and 451-03-66/2024-03/200175 (Institute of Technical Sciences of SASA).

The authors acknowledge the NITRA for financial support to bilateral project between Serbia and Turkey [No (RS) 026-02-06 and No TR (123N941)]. 

Files

Designing and the anticancer activity of chitosan...d4ra05783j.pdf

Files (935.6 kB)

Additional details

Dates

Accepted
2024-09-25
Issued
2024-10-04

Software